Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Will Go After MACE Indication For Victoza Based On LEADER

This article was originally published in The Pink Sheet Daily

Executive Summary

Positive cardiovascular outcomes data for Victoza were outlined at ADA, and Novo Nordisk said it plans to file an sNDA with FDA seeking a broad indication to include reduction in major adverse cardiac events (MACE). The indication is different than the one Lilly is pursuing for Jardiance.


Related Content

Victoza’s Non-Cardio Safety May Dominate At FDA Panel Review
Disappointing Bydureon EXSCEL Outcomes Data May Raise Stakes For Victoza
Keeping Track: New Submissions In Bladder Cancer, HCV And Diabetes; Avastin Label Expands
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission


Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts